+91-8668442535

Respiratory Inhalers Market By Type (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Asthma, Chronic Obstructive Pulmonary Disorder, Pulmonary Arterial Hypertension, Cystic Fibrosis), By Technology (Digital, Manual) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Respiratory inhalers are used to administer an extensive range of medications, such as beta-agonists, anticholinergics, corticosteroids, and certain antibiotics. Respiratory inhalers are used to provide relief of symptoms in various respiratory conditions such as asthma, chronic obstructive pulmonary disorder (COPD), pulmonary arterial hypertension, bronchitis, and cystic fibrosis. In such respiratory conditions, both mild and severe symptoms occur, such as coughing, shortness of breath, chest congestion, respiratory discomfort, and even death in extreme cases. Thus, it becomes important to relieve the symptoms immediately, which is accomplished by the use of inhalers.

Drug administration by inhalers is most widely prescribed as it requires smaller doses to give quick relief, thus reducing the risk of side effects compared to oral medications. The rise in the prevalence of the aforementioned respiratory conditions and the continuous rise in environmental pollution have led to the growth of the respiratory inhaler market in the current and forecast periods of 2017–2025.

The current research report on respiratory inhalers offers an in-depth look at market trends and dynamics. The report includes market estimations and forecast data for the period 2017–2025.

The market has been analyzed and studied into various segments, which are as follows:

Type

  • Dry powder inhalers
  • Metered-dose inhalers
  • Pressurized
  • Breath-actuated
  • Non-pressurized

Nebulizers

  • Jet nebulizer
  • Mesh nebulizer
  • Ultrasonic nebulizer

Application

  • Asthma
  • Chronic Obstructive Pulmonary Disorder
  • pulmonary arterial hypertension
  • Cystic Fibrosis
  • Others

Technology

  • Digital
  • Manual

The respiratory inhaler market has also been studied across geographies. For the purpose of this study, the respiratory inhalers market is segmented based on geography as follows:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Market evaluation and forecast analysis for the above-mentioned segments for the period 2015–2025 have been incorporated into this report. The values have been expressed in million US dollars. Furthermore, the respective growth rates for each of the mentioned segments have also been inculcated with 2016 as the base year.

This report also encompasses qualitative insights with respect to market restraints, opportunities, and drivers. These insights provide an overview of the entire market and would assist emerging players in strategizing their product growth within this market. A competitive landscape depicting the market position of the industrial players has also been incorporated into this report. Company profiles of each of the industrial leaders with respect to financial performance, product portfolio, current market trends, and general information have been incorporated.

The profiles of major industrial leaders incorporated are Boehringer Ingelheim GmbH, Astra Zeneca, PARI Medical Holding, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., GlaxoSmithKline plc, Beximco Pharmaceuticals Ltd., Sandoz, Baxter International, OMRON Healthcare Europe B.V., Propeller Health, Adherium, and others.

Based on type, the global respiratory inhalers market is segmented as follows:

  • Dry powder inhalers
  • Metered-dose inhalers

Respiratory inhalers are the most widely used dosage forms to treat mild to severe respiratory conditions. The market for respiratory inhalers comprises varied kinds of inhalers, such as dry powder inhalers, metered dose inhalers, and nebulizers, which are prescribed based on the severity of the condition and the medication used. Metered dose inhalers dominated the respiratory inhaler market among the aforementioned inhaler types and would continue to do so throughout the forecast period. Because they do not require a deep breath while inhaling, these devices are easily portable and can be used by patients suffering from a variety of respiratory conditions, increasing demand for these products.

Dry powder inhalers are comparatively less expensive, but they require precautions to be taken while handling the medication. Dry powder inhalers are made up of moisture-sensitive capsules, so high humidity may affect the medication. These inhalers require a deep and fast breath to be taken, which could be difficult for certain patients suffering from severe respiratory conditions.

Nebulizers are widely used for pediatric patients as they are easy to administer to infants. Nebulizers are less efficacious than metered-dose inhalers as some of the medication remains on the nebulizer device, thus administering a lesser dose than required. During the forecast period, the nebulizer market will be driven by technological advancements that allow for more effective medication delivery.

Based on application, the global respiratory inhalers market is segmented as follows:

  • Asthma
  • Chronic Obstructive Pulmonary Disorder
  • pulmonary arterial hypertension
  • Cystic Fibrosis
  • Other illnesses (acute bronchitis, pneumonia, and influenza)

Respiratory inhalers are used for the administration of medication for respiratory conditions such as asthma, chronic obstructive pulmonary disorder (COPD), pulmonary arterial hypertension, cystic fibrosis, and other respiratory diseases. Of the above-mentioned respiratory conditions, COPD holds a predominant position in the respiratory inhaler market. As per the World Health Organization, COPD had a prevalence of 251 million patients globally in 2016. This number is expected to rise further in the forecast period. According to the World Health Organization, COPD will be the third leading cause of death by 2030.

Thus, this segment is expected to show remunerative growth in the forecast period. Additionally, COPD treatment presently incorporates combination therapy, which is more efficacious, contributing further to the growth of the respiratory inhaler market. Asthma held the second position in the global respiratory inhaler market. It is the most widely prevalent condition with no permanent cure, but therapies provide symptomatic relief when required. Respiratory inhalers are predominantly used for medication, so this segment would contribute to the lucrative growth of the respiratory inhalers market during the forecast period.

Based on technology, the global respiratory inhalers market is segmented as follows:

  • Digital
  • Manual

Manual respiratory inhalers currently dominate the market as they are widely available and affordable across geographies. The digital segment is expected to grow in the forecast period owing to the emergence of smart inhalers on the market. Digital inhalers enable the recovery of real-time data, which could be recovered at any point in time. Adherium's smart touch inhaler with Bluetooth technology, for example, has entered the market alongside AstraZeneca's drug Symbicort aerosol inhaler.

Moreover, the collaboration between Propeller Health and Novartis to develop a dry powder inhaler has also contributed to the growth of this market. The device includes an add-on sensor that provides easily monitored dosage data, improves patient adherence, and enables remote monitoring of patients. These advancements are creating demand for respiratory inhalers and increasing patient adherence, and thus the digital segment is projected to show remunerative growth during the forecast period, 2017–2025. Furthermore, the development of a structured digital reimbursement policy for chronic conditions is expected to propel the demand for smart inhalers in the future.

For the purpose of this study, the global respiratory inhalers market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Respiratory inhalers have a broad reach and are available in all geographies. North America held the leading position in the respiratory inhaler market. The availability of respiratory inhalers, the presence of leading industries in this region, the higher economic status of patients, and the constant development of digital health reimbursement policies are the catalysts that drive this market.

The Centers for Medicare and Medicaid Services (CMS) is providing various solutions to organizations to provide reimbursement options for managing chronic conditions with non-face-to-face monitoring patients such as asthma and COPD. Asia Pacific is expected to be the fastest-growing market for respiratory inhalers, owing to the high prevalence of respiratory conditions such as asthma and COPD. The World Health Organization (WHO) states that 80% of deaths occur in low- and middle-income countries. The constant rise in industrialization leading to an increase in pollution has also increased the risk of acquiring respiratory diseases, thus having a positive impact on the respiratory inhaler market in the Asia Pacific during the forecast period, 2017–2025.

Frequently Asked Question:

The market for Respiratory Inhalers Market is expected to reach USD$ 44.1 Bn in 2025.

The Respiratory Inhalers Market is expected to see significant CAGR growth over the coming years, at 5.6 %.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Boehringer Ingelheim GmbH, Astra Zeneca, PARI Medical Holding, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., GlaxoSmithKline plc, Beximco Pharmaceuticals Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Medical Devices
Report ID:   58860
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support